Eighteen healthy males received a single 300 mg oral dose of eprosartan as the commercial wet granulation formulation under fasting conditions and following a high-fat breakfast and a single 20 mg intravenous (i.v.) dose. The pharmacokinetics of i.v. eprosartan (mean 9 S.D.) were characterized by a
PHARMACOKINETICS AND FOOD INTERACTION OF MK-462 IN HEALTHY MALES
โ Scribed by Haiyung Cheng; William J. Polvino; David Sciberras; L. Yogendran; Kristine A. Cerchio; Karen Christie; Timothy V. Olah; Debra McLoughlin; Ian James; J. Douglas Rogers
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 429 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
โฆ Synopsis
A study was conducted to assess the safety, tolerability, and pharmacokinetics of single intravenous (IV) doses of 5-90pgkg-' of MK-462, and the effect of food on the pharmacokinetics of MK-462 administered orally to healthy males. Results of this study indicate that IV doses of MK-462 from 5 to 90pgkg-I are well tolerated. The disposition kinetics of MK-462 were linear for IV doses up to and including 60 pg kg-I. The values of the plasma clearance (CL), steady-state volume of distribution (V,,), plasma terminal half-life (t1/2), and mean residence time in the body (MRT) of MK-462 averaged 1376mLminP1, 140 L, 1.8 h, and 1-7 h, respectively, and remained essentially constant over the dosage range of 10-60 pg kg-I of IV MK-462. However, as the dose increased from 60 to 90pgkg-l, the mean value of the apparent CL decreased from 1376 to 807mLmin-'. Thus, elimination of MK-462 was dose dependent in this dosage range. Based on the disposition decomposition analysis (DDA), it was shown that the V,, value of MK-462 remained essentially constant over the dosage range of 10-90 pg kg-I of IV MK-462. The following values of two dose-independent parameters were also calculated by using DDA: distribution clearance (CL,) = 2028 mL min-I, and mean transit time in the peripheral tissues (MTT,) = 0.74 h. The mean values of AUC, C, , , t,,, and apparent tIl2 of MK-462 in 12 subjects each receiving a 40mg tablet of MK-462 without breakfast were 330ng.hmL-I, 77ngmL-', 1.6h, and 1.8 h, respectively. Although administration of a standard breakfast prior to dosing increased the AUC value (by -20%) of MK-462 and delayed its absorption, there were no significant effects of the meal on the values of C,, and apparent tIl2 of MK-462.
๐ SIMILAR VOLUMES
A study was conducted to (i) characterize the multiple-dose pharmacokinetics of oral montelukast sodium (MK-0476), 10 mg d 71 in healthy young subjects (N 12), (ii) evaluate the pharmacokinetics of montelukast in healthy elderly subjects (N 12), and (iii) compare the pharmacokinetics and oral bioava
The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg
The pharmacokinetic disposition and relative bioavailability of sertindole administered as a tablet dosage form under fasting conditions, in the presence of food, in the presence of antacid, and as solution was studied in a four-way crossover in young healthy male volunteers. Overall, tablet dosing
The effect of food on the pharmacokinetics of BMS-181101, a new anti-depressant under development, was investigated in 12 healthy male volunteers at steady state. Each subject received a 15 mg oral dose of BMS-181101 twice a day (q 12 h) for 11 days and a morning dose of BMS-181101 on day 12. Six su